Epoch Investment Partners Inc. Sells 36,042 Shares of IDEXX Laboratories, Inc. $IDXX

Epoch Investment Partners Inc. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 195,799 shares of the company’s stock after selling 36,042 shares during the period. Epoch Investment Partners Inc.’s holdings in IDEXX Laboratories were worth $132,464,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in IDXX. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories during the 4th quarter worth $29,000. WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.5%

Shares of NASDAQ IDXX opened at $560.88 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market capitalization of $44.24 billion, a P/E ratio of 41.30, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The business has a fifty day moving average price of $563.06 and a 200 day moving average price of $627.69.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IDXX shares. UBS Group dropped their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.